Adams Clinical, a Watertown, MA-based provider of a clinical trial site network, received an investment from InTandem Capital Partners.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Nelson Rutrick, Adams Clinical offers a site network for advancing research of the central nervous system. Its expertise, technologies, and recruitment and retention mechanisms ensure it generates outcomes for its participants, sponsors and CROs.
Commenting on the news, Nelson Rutrick said: “We value InTandem’s integrated investment and operating strategy, which is tailored for companies like ours at an inflection point. The InTandem team’s wealth of industry knowledge will enable us to develop a world-class site network that benefits both our pharmaceutical company customers and the patients who ultimately are prescribed drugs we tested.”